Cantor Fitzgerald Predicts AVITA Medical FY2025 Earnings

AVITA Medical, Inc. (NASDAQ:RCEL) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for AVITA Medical in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn anticipates that the company will earn ($1.14) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $21.00 price objective on the stock. The consensus estimate for AVITA Medical’s current full-year earnings is ($2.35) per share.

AVITA Medical (NASDAQ:RCEL) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.21). The business had revenue of $19.55 million for the quarter, compared to the consensus estimate of $19.65 million. AVITA Medical had a negative net margin of 95.47% and a negative return on equity of 194.69%. During the same quarter last year, the business earned ($0.34) EPS.

Other equities analysts also recently issued research reports about the stock. Piper Sandler restated a “neutral” rating and set a $12.00 price objective (up previously from $9.00) on shares of AVITA Medical in a report on Friday, November 8th. Lake Street Capital decreased their target price on AVITA Medical from $20.00 to $14.00 and set a “buy” rating on the stock in a research report on Wednesday, January 8th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $25.00 price objective on shares of AVITA Medical in a research note on Wednesday, January 8th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $18.00.

AVITA Medical Stock Performance

RCEL stock opened at $8.73 on Wednesday. The company has a market capitalization of $228.88 million, a P/E ratio of -3.91 and a beta of 1.58. AVITA Medical has a 1-year low of $7.51 and a 1-year high of $18.93. The company has a debt-to-equity ratio of 3.48, a current ratio of 3.73 and a quick ratio of 3.37. The business has a 50-day moving average price of $12.03 and a 200 day moving average price of $10.67.

Institutional Investors Weigh In On AVITA Medical

A number of institutional investors have recently added to or reduced their stakes in the business. Huntington National Bank purchased a new position in shares of AVITA Medical during the 3rd quarter worth $32,000. FMR LLC boosted its position in AVITA Medical by 126.9% in the 3rd quarter. FMR LLC now owns 4,248 shares of the company’s stock valued at $46,000 after buying an additional 2,376 shares during the last quarter. Quest Partners LLC increased its position in shares of AVITA Medical by 269.4% during the third quarter. Quest Partners LLC now owns 7,520 shares of the company’s stock worth $81,000 after acquiring an additional 5,484 shares during the last quarter. The Manufacturers Life Insurance Company purchased a new position in shares of AVITA Medical during the 2nd quarter valued at approximately $86,000. Finally, SG Americas Securities LLC acquired a new stake in shares of AVITA Medical in the 4th quarter valued at about $190,000. Hedge funds and other institutional investors own 27.66% of the company’s stock.

AVITA Medical Company Profile

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.